A federal advisory panel backed the approval of a Seattle Genetics Inc. (SGEN) experimental drug as a Hodgkin lymphoma treatment. The drug, which has a generic name of brentuximab vodotin and a proposed brand name of Adcetris, is currently under review by the U.S. Food and Drug Administration for two types of lymphoma that have not responded to other treatments; Hodgkin lymphoma and anaplastic large cell lymphoma. A panel of non-FDA medical experts is discussing Adcetris at a meeting Thursday.
